Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Home (current)
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    CAR-TCR Global 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

Trial Updates

MOMENTUM: ARU-1801 in sickle cell disease 1:57
MOMENTUM: ARU-1801 in sickle cell disease
Will Chou • 26 Jan 2022
DSG3-CAART: A novel CAAR T-cell therapy in pemphigus vulgaris 2:23
DSG3-CAART: A novel CAAR T-cell therapy in pemphigus vulgaris
Samik Basu • 26 Jan 2022
jCell: allogeneic cell therapy for retinitis pigmentosa 1:57
jCell: allogeneic cell therapy for retinitis pigmentosa
Gil Carrasquinho • 2 Jul 2021
RP-L301 lentiviral gene therapy for PKD 3:47
RP-L301 lentiviral gene therapy for PKD
Jose-Luis López-Lorenzo • 15 Nov 2021
An update on the Phase I trial evaluating RP-L301 in PKD 7:24
An update on the Phase I trial evaluating RP-L301 in PKD
Jose-Luis López-Lorenzo • 15 Nov 2021
LYS-GM101 AAV gene therapy for GM1 gangliosidosis 6:19
LYS-GM101 AAV gene therapy for GM1 gangliosidosis
Michael Hocquemiller • 15 Nov 2021
GNT0003: AAV gene therapy for Crigler-Najjar syndrome 3:42
GNT0003: AAV gene therapy for Crigler-Najjar syndrome
Lorenzo D'Antiga • 18 Nov 2021
The safety of AVR-RD-01 gene therapy for Fabry disease 4:31
The safety of AVR-RD-01 gene therapy for Fabry disease
Mark Thomas • 29 Oct 2021
LYS-SAF302 AAV gene therapy for MPS IIIA 2:38
LYS-SAF302 AAV gene therapy for MPS IIIA
Michael Hocquemiller • 15 Nov 2021
Overcoming immunogenicity of gene therapies 1:16
Overcoming immunogenicity of gene therapies
Timothy Miller • 18 Nov 2021
RESKUE: AAV-based gene therapy for Krabbe disease 0:59
RESKUE: AAV-based gene therapy for Krabbe disease
Timothy Miller • 18 Nov 2021
ATA3219, ATA3271 & ATA188: T-Cell immunotherapy products in development 3:59
ATA3219, ATA3271 & ATA188: T-Cell immunotherapy products in development
Pascal Touchon • 22 Oct 2021
AAV-based gene therapy for X-linked retinitis pigmentosa 2:03
AAV-based gene therapy for X-linked retinitis pigmentosa
Sue Washer • 22 Oct 2021
Optogenetics in advanced retinitis pigmentosa 1:52
Optogenetics in advanced retinitis pigmentosa
Sue Washer • 22 Oct 2021
Treating achromatopsia with AAV-based gene therapy 2:12
Treating achromatopsia with AAV-based gene therapy
Sue Washer • 22 Oct 2021
LUMEVOQ gene therapy for LHON 2:40
LUMEVOQ gene therapy for LHON
Magali Taiel • 6 Oct 2021
  • 1
  • 2
  • 3
  • Next
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy